# EDGAR Filing Document

**Accession Number:** 0001898416
**File Stem:** 0000930413-26-001856
**Filing Date:** 2026-6
**Character Count:** 3589
**Document Hash:** be114a5e4ed310664aa4d704eb14796d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000930413-26-001856.hdr.sgml**: 20260615

**ACCESSION NUMBER**: 0000930413-26-001856

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260615

**FILED AS OF DATE**: 20260615

**DATE AS OF CHANGE**: 20260615

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alvotech
- **CENTRAL INDEX KEY:** 0001898416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981629342
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41421
- **FILM NUMBER:** 261090756

**BUSINESS ADDRESS:**
- **STREET 1:** 9, RUE DE BITBOURG
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-1273
- **BUSINESS PHONE:** 354 422-4500

**MAIL ADDRESS:**
- **STREET 1:** 9, RUE DE BITBOURG
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-1273

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alvotech Lux Holdings S.A.S.
- **DATE OF NAME CHANGE:** 20211209

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June 2026**

**Commission File Number: 001-41421**

**Alvotech**

**(Translation of registrant's name into English)**

**9, Rue de Bitbourg,** 

**L-1273 Luxembourg,** 

**Grand Duchy of Luxembourg** 

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

**Termination of ATM Prospectus Supplement**

On June 15, 2026, the Company notified Jefferies LLC that it was suspending its use of and terminating the prospectus supplement (the "<u>ATM Prospectus Supplement</u>"), related to the potential issuance from time to time of the Company's ordinary shares pursuant to the Open Market Sale Agreement<sup>SM</sup>, dated June 14, 2024, by and between the Company and Jefferies LLC (the "<u>Sales Agreement</u>"). The Company will not make any sales of its securities pursuant to the Sales Agreement unless and until a new prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus Supplement, the Sales Agreement remains in full force and effect.

**INCORPORATION BY REFERENCE**

This Report shall be deemed to be incorporated by reference into the Company's registration statements on Form F-3 (File Nos. 333-266136, 333-273262, 333-275111, and 333-281684), the Company's registration statement on Form F-3ASR (File No. 333-289006), and the Company's registration statement on Form S-8 (File No. 333-266881), including any prospectuses forming a part of such registration statements, and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **ALVOTECH** | **ALVOTECH** | **ALVOTECH** |
| Date: | June 15, 2026 | By: | /s/ Tanya Zharov | /s/ Tanya Zharov |
|  |  |  | Name: | Tanya Zharov |
|  |  |  | Title: | General Counsel |

---